Moonlake Immunotherapeutics (MLTX) — 10-Q Filings
All 10-Q filings from Moonlake Immunotherapeutics. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
- 10-Q Filing — May 11, 2026
-
MoonLake's Losses Widen on Soaring R&D for Key Drug Sonelokimab
— Nov 5, 2025 Risk: high
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, reported a significant increase in net loss for the nine months ended September 30, 2025, r -
MoonLake Immunotherapeutics: No Revenue, Focus on Clinical Pipeline
— Aug 5, 2025 Risk: high
MoonLake Immunotherapeutics reported no revenue for the six months ended June 30, 2025, consistent with its clinical-stage status. The company's net loss for th -
MoonLake Immunotherapeutics Files Q1 2025 10-Q
— May 12, 2025 Risk: low
MoonLake Immunotherapeutics filed its 10-Q for the period ending March 31, 2025. The company, formerly Helix Acquisition Corp, is in the pharmaceutical preparat -
MoonLake Immunotherapeutics Files Q3 2024 10-Q
— Nov 7, 2024 Risk: medium
MoonLake Immunotherapeutics filed its 10-Q for the period ending September 30, 2024. The company, formerly Helix Acquisition Corp, is focused on pharmaceutical -
MoonLake Immunotherapeutics Files Q2 2024 10-Q
— Aug 7, 2024 Risk: medium
MoonLake Immunotherapeutics filed its 10-Q for the period ending June 30, 2024. The company, formerly Helix Acquisition Corp, is focused on pharmaceutical prepa
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX